SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4
http://www.w3.org/2000/01/rdf-schema#comment
"However toxicity issues remain a problem for ceritinib and another next-generation ALK inhibitor alectinib is more likely to become the drug of choice for untreated patients"
xsd:string
http://purl.uniprot.org/uniprot/#_9540C9A242F3049B1283EB42BF661675F064AA8F1E2A33C1C99D5522760168BA99FE9EB9E059F1153D3B09373FB90647
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4
http://purl.uniprot.org/uniprot/B2MXE5
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4
http://purl.uniprot.org/uniprot/#_B2MXE5-mappedCitation-28193771
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D49C590D4EA4D9CAA75CA73FA6C817F46698C6D5F9C07431F855CBD61A8AC0374BCD1BA293E520C227597D207FFCBEA4